Sage Journals: Discover world-class research

Abstract

Objective:

The present study aimed to examine affecting factors for conversion ratio and to predict adequate fentanyl dose for patients with cancer pain in opioid switching from oral oxycodone.

Methods:

Patient characteristics, biochemical parameters, daily oxycodone dose, and reasons for opioid switching were retrospectively collected. The effect of variables on the conversion ratio was analyzed by multiple regression analysis.

Results:

Regression analysis for the data from 122 patients suggested that the typical conversion ratio was 95:1; however, this ratio was significantly reduced in patients taking a daily oral morphine-equivalent dose of <45 mg/d and in patients with poor pain control to 52:1 and 64:1, respectively.

Conclusion:

We should carefully and rapidly control pain in opioid switching based on the adequate dose indicated in this study.

Keywords

opioid switching transdermal fentanyl oral oxycodone pain control conversion ratio patients with cancer

Get full access to this article

View all access options for this article.

References

Maltoni

Scarpi

Modonesi

. A validation study of the WHO analgesic ladder: a two-step vs three-step strategy. Support Care Cancer. 2005;13(11):888–894.

Mercadante

Casuccio

Fulfaro

. Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: a prospective study. J Clin Oncol. 2001;19(11):2898–2904.

Indelicato

Portenoy

. Opioid rotation in the management of refractory cancer pain. J Clin Oncol. 2002;20(1):348–352.

Caraceni

Hanks

Kaasa

. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol. 2012;13(2):e58–e68.

Rowbotham

Wyld

Peacock

Duthie

Nimmo

. Transdermal fentanyl for the relief of pain after upper abdominal surgery. Br J Anaesth. 1989;63(1):56–59.

Mercadante

Caraceni

. Conversion ratios for opioid switching in the treatment of cancer pain: a systematic review. Palliat Med. 2011;25(5):504–515.

Donner

Zenz

Tryba

Strumpf

. Direct conversion from oral morphine to transdermal fentanyl: a multicenter study in patients with cancer pain. Pain. 1996;64(3):527–534.

Akiyama

Iseki

Izawa

. Usefulness of fentanyl patch (Durotep) in cancer patients when rotated from morphine preparations [in Japanese]. Masui. 2007;56(3):317–223.

Nalamachu

. Opioid rotation in clinical practice. Adv Ther. 2012;29(10):849–863.

10.

Muijsers

Wagstaff

. Transdermal fentanyl: an updated review of its pharmacological properties and therapeutic efficacy in chronic cancer pain control. Drugs. 2001;61(15):2289–2307.

11.

Menten

Desmedt

Lossignol

Mullie

. Longitudinal follow-up of TTS-fentanyl use in patients with cancer-related pain: results of a compassionate-use study with special focus on elderly patients. Curr Med Res Opin. 2002;18(8):488–498.

12.

Gupta

Southam

Gale

Hwang

. System functionality and physicochemical model of fentanyl transdermal system. J Pain Symptom Manage. 1992;7(3):S17–S26.

13.

Heiskanen

Mätzke

Haakana

Gergov

Vuori

Kalso

. Transdermal fentanyl in cachectic cancer patients. Pain. 2009;144(1-2):218–222.

14.

Kanbayashi

Hosokawa

Okamoto

. Factors predicting requirement of high-dose transdermal fentanyl in opioid switching from oral morphine or oxycodone in patients with cancer pain. Clin J Pain. 2011;27(8):664–667.

15.

Heiskanen

Kalso

. Controlled-release oxycodone and morphine in cancer related pain. Pain. 1997;73(1):37–45.

16.

Duregesic (Fentanyl Transdermal System) Full Prescribing Information . Titusville, NJ: Ortho-McNeil-Janssen Pharmaceuticals, Inc.; 2008.

17.

Solassol

Bressolle

Caumette

. Inter- and intraindividual variabilities in pharmacokinetics of fentanyl after repeated 72-hour transdermal applications in cancer pain patients. Ther Drug Monit. 2005;14(4):1029–1036.

18.

Kato

Mizaki

Yamazaki

. A study of transdermal fentanyl in cancer pain at Aichi-Cancer Center. Yakugaku Zasshi. 2004;124(5):287–291. (in Japanese).

19.

Ogawa

Nakamura

Iizuka

Sekizuka

Yamamoto

Horiuchi

. Optimal conversion ratio of oral morphine to transdermal fentanyl patches to the cancer pain [in Japanese]. Yakugaku Zasshi. 2009;129(3):335–340.

Indication of Adequate Transdermal Fentanyl Dose in Opioid Switching From Oral Oxycodone in Patients With Cancer